The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; none of the 41 sources its claims cite is checked for support yet.
Virus-Dependent Phosphorylation of the IRF-3 Transcription Factor Regulates Nuclear Translocation, Transactivation Potential, and Proteasome-Mediated Degradation
Open accessAbstract
The interferon regulatory factors (IRF) consist of a growing family of related transcription proteins first identified as regulators of the alpha beta interferon (IFN-alpha/beta) gene promoters, as well as the interferon-stimulated response element (ISRE) of some IFN-stimulated genes. IRF-3 was originally identified as a member of the IRF family based on homology with other IRF family members and on binding to the ISRE of the ISG15 promoter. IRF-3 is expressed constitutively in a variety of tissues, and the relative levels of IRF-3 mRNA do not change in virus-infected or IFN-treated cells. In the present study, we demonstrate that following Sendai virus infection, IRF-3 is posttranslationally modified by protein phosphorylation at multiple serine and threonine residues, which are located in the carboxy terminus of IRF-3. A combination of IRF-3 deletion and point mutations localized the inducible phosphorylation sites to the region -ISNSHPLSLTSDQ- between amino acids 395 and 407; point mutation of residues Ser-396 and Ser-398 eliminated virus-induced phosphorylation of IRF-3 protein, although residues Ser-402, Thr-404, and Ser-405 were also targets. Phosphorylation results in the cytoplasm-to-nucleus translocation of IRF-3, DNA binding, and increased transcriptional activation. Substitution of the Ser-Thr sites with the phosphomimetic Asp generated a constitutively active form of IRF-3 that functioned as a very strong activator of promoters containing PRDI-PRDIII or ISRE regulatory elements. Phosphorylation also appears to represent a signal for virus-mediated degradation, since the virus-induced turnover of IRF-3 was prevented by mutation of the IRF-3 Ser-Thr cluster or by proteasome inhibitors. Interestingly, virus infection resulted in the association of IRF-3 with the CREB binding protein (CBP) coactivator, as detected by coimmunoprecipitation with anti-CBP antibody, an interaction mediated by the C-terminal domains of both proteins. Mutation of residues Ser-396 and Ser-398 in IRF-3 abrogated its binding to CBP. These results are discussed in terms of a model in which virus-inducible, C-terminal phosphorylation of IRF-3 alters protein conformation to permit nuclear translocation, association with transcriptional partners, and primary activation of IFN- and IFN-responsive genes.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In Sendai virus-infected cells, IRF-3 is phosphorylated at C-terminal Ser/Thr residues, which drives nuclear translocation, DNA binding/transactivation, CBP association, and subsequent proteasome-mediated degradation. Phosphomimetic IRF-3(5D) acts as a constitutive strong activator of IFN-β and ISG-15 promoters.
Key findings
- Virus-induced phosphorylation mapped to the C-terminal region -ISNSHPLSLTSDQ- between amino acids 395 and 407; Ser-396 and Ser-398 were critical, since IRF-3(2A) and IRF-3(5A) eliminated virus-induced phosphorylation, while IRF-3(3A) was weakly phosphorylated, implicating Ser-402, Thr-404, and Ser-405 as secondary sites.
- Phosphorylation was required for cytoplasm-to-nucleus translocation: Sendai virus induced nuclear translocation in 90 to 95% of cells within 8 h, GFP–IRF-3(5A) completely abrogated this, and GFP–IRF-3(5D) localized partly to the nucleus in uninfected cells and intensely to the nucleus after infection.
- IRF-3(5D) alone stimulated the IFN-β promoter by 90-fold and the ISG-15 promoter by 50-fold; with RelA(p65), IRF-3(5D) produced an 80-fold stimulation of IFN-β, while IRF-3(407) stimulated IFN-β about 6-fold and ISG-15 12-fold.
- Phosphorylation signaled proteasome-mediated degradation and CBP binding: calpain inhibitor I or MG132 blocked virus-induced IRF-3 degradation, IRF-3(5A) was resistant, and IRF-3 coimmunoprecipitated with CBP only from virus-infected cells, requiring Ser-396/Ser-398 and the C-terminal CBP-3 domain.
Methods
- Transient transfections were performed in human embryonic kidney 293 cells, murine NIH 3T3 cells, and COS-7 cells, plus a stable rtTA-IRF-3 293 line; cells were infected with Sendai virus at 80 hemagglutinating units/ml, and IRF-3 deletion and point mutants were generated by PCR mutagenesis.
- Analyses included Western blotting for IRF-3 mobility and degradation, phosphatase treatment with PPA or CIP, CAT reporter assays for IFN-β (SVoβ CAT) and ISG-15 promoters normalized to β-galactosidase, EMSA with PRDIII or ISRE probes, GFP–IRF-3 fluorescence microscopy, and coimmunoprecipitation with anti-CBP or anti-myc antibodies.
Limitations
- The paper states that the nature of the subnuclear changes in IRF-3(NES) localization is not explained, it is unclear whether the upper virus-induced protein-DNA complex contains other proteins such as VIC or DRAF or whether the lower complex is an IRF-3 breakdown product, the functional consequences of IRF-3 interaction with CBP/p300 remain to be elucidated, and the nuclear localization sequence is unidentified.
- Evident from the text: many experiments rely on transfected or overexpressed IRF-3 in immortalized cell lines, with endogenous IRF-3 turnover sometimes more pronounced than that of transfected protein; no in vivo animal model is presented, and some supporting observations are cited as unpublished data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 41 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of the Ser-Thr sites with the phosphomimetic Asp generated a constitutively active form of IRF-3 that functioned as a very strong activator of promoters containing PRDI-PRDIII or ISRE regulatory elements.”
- Also stated in: § RESULTS · boosted
“Strikingly, the substitution of the Ser-Thr cluster at aa 396 to 405 in IRF-3 with the phosphomimetic Asp generated a very strong, constitutive transactivator protein that alone stimulated the IFN-β promoter by 90-fold.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“point mutation of residues Ser-396 and Ser-398 eliminated virus-induced phosphorylation of IRF-3 protein”
- Also stated in: § RESULTS · hedged
“These experiments thus implicate Ser-396 and Ser-398 as critical sites of virus-induced phosphorylation of IRF-3”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A combination of IRF-3 deletion and point mutations localized the inducible phosphorylation sites to the region -ISNSHPLSLTSDQ- between amino acids 395 and 407”
- Also stated in: § RESULTS · plain
“Thus, by deletion analysis, a phosphorylation domain of IRF-3 protein was localized to the region -ISNSHPLSLTSDQ- between aa 395 and 407.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in studies with the S385A and S386A mutation, we found no evidence for inducible phosphorylation at these sites”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“although residues Ser-402, Thr-404, and Ser-405 were also targets.”
- Also stated in: § RESULTS · plain
“residues Ser-402, Thr-404, and Ser-405 also contribute to the observed phosphorylation”
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the present study, we demonstrate that following Sendai virus infection, IRF-3 is posttranslationally modified by protein phosphorylation at multiple serine and threonine residues, which are located in the carboxy terminus of IRF-3.”
- Also stated in: § RESULTS · hedged
“The results indicated that virus-induced phosphorylation of IRF-3 occurs at the C-terminal end of IRF-3”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Sendai virus infection resulted in two alterations in the expression of IRF-3: an overall decrease in the amount of IRF-3 in transfected and control cells”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, in uninfected cells, IRF-3(5D) localized in part to the nucleus (Fig. 5)”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: Phosphomimetic Asp at the sites of C-terminal phosphorylation functionally mimics phosphorylation.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the IRF-3-ΔN5A protein was resistant to virus-induced degradation”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, virus infection resulted in the association of IRF-3 with the CREB binding protein (CBP) coactivator, as detected by coimmunoprecipitation with anti-CBP antibody”
- Also stated in: § RESULTS · plain
“an immunoblot for IRF-3 revealed that IRF-3 was coprecipitated from virus-infected cells but not from uninfected cells”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
- It may state two separate claims as one. 23
- Probably not a substantial claim. 21
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The residues implicated in this regulatory phosphorylation event are Ser-396, Ser-398, Ser-402, Thr-404, and Ser-405, particularly the Ser-396 and Ser-398 residues.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IRF-3(357) did not stimulate gene expression but rather slightly repressed ISG-15”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IRF-3 alone weakly activated the ISG-15 promoter; in the context of this regulatory element, IRF-3 was weaker than IRF-1, which produced a 9-fold stimulation”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This interaction was observed clearly in cells cotransfected with the IRF-3 expression plasmid (Fig. 8B, lane 3) but was not seen when the immunoprecipitation was performed with preimmune serum”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Immunoblot analysis of the whole-cell extracts revealed that phosphorylated IRF-3, as well as forms I and II, was present in virus-infected cells (Fig. 8B, lane 10), and in cells transfected with 2A, 3A, and 5A the forms I and II but not the phosphorylated form of IRF-3 were observed”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In uninfected cells, GFP–IRF-3 localized exclusively to the cytoplasm; Sendai virus infection resulted in translocation of IRF-3 to the nucleus within 8 h in 90 to 95% of the cells”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“virus-induced degradation of full-length (endogenous) forms of IRF-3 (Fig. 7A, lanes 1 and 4) and the truncated ΔN (Fig. 7B, lanes 1 and 4) was detected”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IRF-3(2A) and IRF-3(5A) were detected in whole-cell extract immunoblot but not in the CBP immunoprecipitate”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“no further stabilization of IRF-3-ΔN5A occurred with calpain inhibitor I or MG132 addition, and no phosphorylated IRF-3 was detected”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IRF-3(5D) localized both to the nucleus and to the cytoplasm in uninfected cells (Fig. 5E), while virus infection resulted in an intense nuclear pattern of IRF-3(5D) fluorescence”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In the case of IRF-3, phosphorylation is not detected until 6 to 8 h after infection and continues in a heterogeneous manner over the following 10 to 12 h.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“whereas IRF-3 phosphorylation appears to be induced only by virus infection and dsRNA addition; other inducers have not resulted in IRF-3 turnover (40a).”
What the sources say
- Not checked yetcites 40a
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Furthermore, the protease inhibitor calpain inhibitor I and the more specific proteasome inhibitor MG132 block IRF-3 turnover.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“since mutation of Ser-396 and Ser-398 or the use of proteasome inhibitors prevented postinfection degradation of IRF-3.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“IRF-3 is expressed constitutively in a variety of tissues, and the relative levels of IRF-3 mRNA do not change in virus-infected or IFN-treated cells.”
- Also stated in: § Abstract · plain
“The IRF-3 gene encodes a 55-kDa protein which is expressed constitutively in all tissues.”
What the sources say
- Not checked yetcites [2] Au W-C, Moore P A, Lowther W, Juang Y-T, Pitha P M. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci USA. 1995;92:11657–11661. doi: 10.1073/pnas.92.25.11657. [DOI] [PMC free article] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Abstract · plain
None of the sources cited for this claim have been checked yet.
In the paper
“As a critical determinant of its global transcriptional coactivator activity, CBP/p300 possesses histone acetyltransferase activity (5, 50).”
What the sources say
- Not checked yetcites [5] Bannister A J, Kouzarides T. The CBP coactivator is a histone acetyltransferase. Nature. 1996;384:641–643. doi: 10.1038/384641a0. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [50] Ogryzko V V, Schiltz R L, Russanova V, Howard B H, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87:953–959. doi: 10.1016/s0092-8674(00)82001-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results are discussed in terms of a model in which virus-inducible, C-terminal phosphorylation of IRF-3 alters protein conformation to permit nuclear translocation, association with transcriptional partners, and primary activation of IFN- and IFN-responsive genes.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The recent crystal structure of the related IRF-1 protein bound to PRDI provides evidence for a novel helix-turn-helix motif that latches onto a GAAA core sequence via three of the five conserved tryptophan amino acids of the DNA binding domain (20).”
What the sources say
- Not checked yetcites [20] Escalante C R, Yie J, Thanos D, Aggarwal A K. Structure of IRF-1 with bound DNA reveals determinants of interferon regulation. Nature. 1998;391:103–106. doi: 10.1038/34224. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“In previous experiments, we demonstrated that IRF-3 was able to bind the ISRE element of ISG-15, as well as the PRDIII-PRDI and IE regions of the IFN-β and IFN-α promoters, respectively (2, 56).”
What the sources say
- Not checked yetcites [2] Au W-C, Moore P A, Lowther W, Juang Y-T, Pitha P M. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci USA. 1995;92:11657–11661. doi: 10.1073/pnas.92.25.11657. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Not checked yetcites [56] Schafer S, Lin R, Moore P, Hiscott J, Pitha P M. Regulation of type 1 interferon gene expression by interferon regulatory factor 3. J Biol Chem. 1998;273:2714–2720. doi: 10.1074/jbc.273.5.2714. [DOI] [PubMed] [Google Scholar]
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Elegant studies published during review of the manuscript demonstrated that synergistic activation of the IFN-β promoter requires recruitment of CBP/p300 to the enhanceosome, via a new activating surface assembled from the activation domains of all of the transcription factors in the enhanceosome (37, 45).”
What the sources say
- Not checked yetcites [37] Kim T K, Maniatis T. The mechanism of transcriptional synergy of an in vitro assembled interferon β enhanceosome. Mol Cell. 1998;1:119–129. doi: 10.1016/s1097-2765(00)80013-1. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [45] Merika M, Williams A, Chen G, Collins T, Thanos D. Recruitment of CBP/p300 by the IFNβ enhanceosome is required for synergistic activation of transcription. Mol Cell. 1998;1:277–287. doi: 10.1016/s1097-2765(00)80028-3. [DOI] [PubMed] [Google Scholar]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“although Ser-402, Ser-404, and Ser-405 may represent secondary phosphorylation sites.”
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Upon stimulation by many activating agents, including cytokines, viruses, and dsRNA, IκBα is rapidly phosphorylated and degraded, resulting in the release and nuclear translocation of NF-κB.”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Although TH3 has been shown to bind DNA and to repress transcription more efficiently than the full-length IRF-2 protein (42)”
What the sources say
- Not checked yetcites [42] Lin R, Mustafa A, Nguyen H, Hiscott J. Mutational analysis of interferon (IFN) regulatory factors 1 and 2: effects on the induction of IFN-β gene expression. J Biol Chem. 1994;269:17542–17549. [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Previous experiments, however, have demonstrated that Sendai virus-induced turnover of IκBα also occurs slowly over several hours (24).”
What the sources say
- Not checked yetcites [24] Garoufalis E, Kwan I, Lin R, Mustafa A, Pepin N, Roulston A, Lacoste J, Hiscott J. Viral induction of the human interferon beta promoter: modulation of transcription by NF-κB/rel proteins and interferon regulatory factors. J Virol. 1994;68:4707–4715. doi: 10.1128/jvi.68.8.4707-4715.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“interestingly, CBP/p300 was shown recently to acetylate p53 and to stimulate its transactivation potential (28).”
What the sources say
- Not checked yetcites [28] Gu W, Roeder R G. Activation of p53 sequence-specific DNA binding by acetylation of p53 C-terminal domain. Cell. 1997;90:595–606. doi: 10.1016/s0092-8674(00)80521-8. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In response to double-stranded RNA (dsRNA) or viral induction, the 50-kDa IRF-2 protein is proteolytically processed into a smaller, 24- to 27-kDa protein (51) comprising the 160-aa DNA-binding domain (DBD) of IRF-2, which was termed TH3 (14) or In4 (65).”
What the sources say
- Not checked yetcites [51] Palombella V J, Maniatis T. Inducible processing of interferon regulatory factor-2. Mol Cell Biol. 1992;12:3325–3336. doi: 10.1128/mcb.12.8.3325-3336.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Not checked yetcites [14] Cohen L, Hiscott J. Characterization of TH3, an induction specific protein interacting with the interferon-β promoter. Virology. 1992;191:589–599. doi: 10.1016/0042-6822(92)90234-g. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [65] Whiteside S T, King P, Goodbourn S. A truncated form of the IRF-2 transcription factor has the properties of a postinduction repressor of interferon-β gene expression. J Biol Chem. 1994;269:27059–27065. [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The amino terminus of IκBα is necessary for signal-induced phosphorylation and ubiquitination, but for degradation to occur, there is an absolute requirement for the C-terminal PEST domain (reviewed in references 4 and 6).”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“substitution of alanine for either Ser-32 or Ser-36 completely abolished the signal-induced phosphorylation and degradation of IκBα and blocked activation of NF-κB.”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In unstimulated cells, NF-κB heterodimers are retained in the cytoplasm by inhibitory IκB proteins.”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“A growing body of biochemical and genetic evidence also implicates CBP/p300 as a negative regulator of cell growth, based on its interactions with adenovirus E1a, simian virus 40 large T antigen, and the tumor suppressor p53 among others.”
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Likewise, in the case of IκBα, phosphorylation of Ser-32 and Ser-36 are required for inducer-mediated degradation.”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Alterations in any of the activation domains decreased both CBP recruitment and transcriptional synergy.”
What the sources say
- Not checked yetcites [37] Kim T K, Maniatis T. The mechanism of transcriptional synergy of an in vitro assembled interferon β enhanceosome. Mol Cell. 1998;1:119–129. doi: 10.1016/s1097-2765(00)80013-1. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [45] Merika M, Williams A, Chen G, Collins T, Thanos D. Recruitment of CBP/p300 by the IFNβ enhanceosome is required for synergistic activation of transcription. Mol Cell. 1998;1:277–287. doi: 10.1016/s1097-2765(00)80028-3. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“functional interaction between these two important growth regulatory proteins accounts for several of the known activities of p53 (3, 29, 40)”
What the sources say
- Not checked yetcites [3] Avantaggiati M L, Ogryzko V, Gardner K, Giordano A, Levine A S, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 1997;89:1175–1184. doi: 10.1016/s0092-8674(00)80304-9. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [29] Gu W, Shi X L, Roeder R G. Synergistic activation of transcription by CBP and p53. Nature. 1997;387:819–823. doi: 10.1038/42972. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [40] Lill N L, Grossman S R, Ginsberg D, DeCaprio J, Livingston D M. Binding and modulation of p53 by p300/CBP coactivators. Nature. 1997;387:823–827. doi: 10.1038/42981. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By analogy, recruitment of CBP/p300 to DNA-bound IRF-3 is likely required for maximal transcriptional activation.”
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Several studies have now demonstrated that CBP/p300 participates in the transcriptional process by providing a scaffold for different classes of transcriptional regulators on specific chromatin domains (12, 50).”
What the sources say
- Not checked yetcites [12] Chen H, Lin R J, Schiltz R L, Chakravarti D, Nash A, Nagy L, Privalsky M L, Nakatani Y, Evans R M. Nuclear receptor coactivator ACTR is a novel histone acetyltransferases and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997;90:569–580. doi: 10.1016/s0092-8674(00)80516-4. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [50] Ogryzko V V, Schiltz R L, Russanova V, Howard B H, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87:953–959. doi: 10.1016/s0092-8674(00)82001-2. [DOI] [PubMed] [Google Scholar]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“These mutations also blocked in vitro ubiquitination of the IκBα protein.”
What the sources say
- Not checked yetcites [4] Baldwin A S., Jr The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–681. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [6] Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996;7:175–190. doi: 10.1016/1359-6101(96)00020-2. [DOI] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“although recent studies demonstrated that CBP/p300 also functionally interacts with STAT1 (68) and STAT2 (7) and may contribute to IFN-α and IFN-γ nuclear signalling.”
What the sources say
- Not checked yetcites [68] Zhang J J, Vinkemeier U, Gu W, Chakravarti D, Horvath C M, Darnell J E. Two contact regions between STAT1 and CBP/p300 in interferon gamma signalling. Proc Natl Acad Sci USA. 1996;93:15092–15096. doi: 10.1073/pnas.93.26.15092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Not checked yetcites [7] Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D’Andrea A, Livingston D M. Cooperation of Stat2 and p300/CBP by interferon-α. Nature. 1996;383:344–347. doi: 10.1038/383344a0. [DOI] [PubMed] [Google Scholar]
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“a region previously shown to associate with the p53 tumor suppressor, whereas STAT1 and STAT2 associate with different regions of CBP (7, 68).”
What the sources say
- Not checked yetcites [7] Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D’Andrea A, Livingston D M. Cooperation of Stat2 and p300/CBP by interferon-α. Nature. 1996;383:344–347. doi: 10.1038/383344a0. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [68] Zhang J J, Vinkemeier U, Gu W, Chakravarti D, Horvath C M, Darnell J E. Two contact regions between STAT1 and CBP/p300 in interferon gamma signalling. Proc Natl Acad Sci USA. 1996;93:15092–15096. doi: 10.1073/pnas.93.26.15092. [DOI] [PMC free article] [PubMed] [Google Scholar]
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Phosphomimetic Asp at the sites of C-terminal phosphorylation functionally mimics phosphorylation.
“IRF-3 containing the phosphomimetic Asp at the sites of C-terminal phosphorylation”
The authors state this as an assumption.
IRF-3 exists in a latent state in the cytoplasm of uninfected cells.
“IRF-3 exists in a latent state in the cytoplasm of uninfected cells”
The authors state this as an assumption.
The C terminus of IRF-3 may physically interact with the DNA binding domain to obscure both the DBD and IAD regions.
“the C terminus may physically interact with the DNA binding domain in such a way as to obscure both the DBD and the IAD regions of the protein”
The authors state this as an assumption.
The C-terminal 20 aa (407 to 427) contains an autoinhibitory domain.
“the presence of an autoinhibitory domain within the C-terminal 20 aa (407 to 427)”
The authors state this as an assumption.
Translocation of IRF-3 to the nucleus occurs via an unidentified nuclear localization sequence or in conjunction with a transcriptional partner associating through the IAD region.
“Translocation to the nucleus, occurring via an unidentified nuclear localization sequence or in conjunction with a transcriptional partner associating through the IAD region”
The authors state this as an assumption.
The presence of a NES element ultimately shuttles IRF-3 from the nucleus and terminates the initial activation of IFN-responsive promoters.
“The presence of a NES element ultimately shuttles IRF-3 from the nucleus and terminates the initial activation of IFN-responsive promoters.”
The authors state this as an assumption.
The phosphorylated form of IRF-3 exported from the nucleus may then be susceptible to proteasome-mediated degradation.
“The phosphorylated form of IRF-3 exported from the nucleus may then be susceptible to proteasome-mediated degradation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IRF-3 possesses a C-terminal autoinhibitory region.Regulated phosphorylation of this region upon viral infection stimulates DNA binding”
From Assembly requirements of PU.1–Pip (IRF‐4) activator complexes: inhibiting function in vivo using fused dimers (1999) · cites this paper as Lin et al., 1998
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Figure 2B lane 6 cited for both presence and disappearance of phosphorylated IRF-3
MinorLane 6 is cited as showing the additional IRF-3 form in infected cells and also as showing its complete disappearance after phosphatase treatment.
“an additional slowly migrating, presumably phosphorylated form of IRF-3 was also detected (Fig. 2B, lane 6)”
“this form of IRF-3 completely disappeared following CIP or PPA treatment (Fig. 2B, lanes 6 and 7)”
Residue 404 identified as both threonine and serine
MinorThe mapped phosphorylation cluster identifies residue 404 as threonine, whereas the discussion calls it serine.
“Ser-402, Thr-404, and Ser-405”
“Ser-402, Ser-404, and Ser-405 may represent secondary phosphorylation sites.”
Different residues identified for the NES mutation
MinorThe results identify the nuclear export signal mutation as L145A-L146A, but the discussion identifies it as L144A and L145A.
“the L145A-L146A modification—termed IRF–3(nuclear export signal [NES])”
“Mutation of L144A and L145A in the NES element produced the most impressive alterations in subcellular localization.”
Citations
Cites
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 5,882
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“The kinetics of virus-induced modification of IRF-3 in a 293 cell line that expressed IRF-3 inducibly under the control of the tetracycline-responsive promoter CMVt were characterized (26, 27).”
MethodThe Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Transcriptional Activation by Tetracyclines in Mammalian Cells
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., & Bujard, H. (1995) · Science · doi:10.1126/science.7792603 · Cited by 2,488 · cited 1×
“The kinetics of virus-induced modification of IRF-3 in a 293 cell line that expressed IRF-3 inducibly under the control of the tetracycline-responsive promoter CMVt were characterized (26, 27).”
MethodPhosphorylated CREB binds specifically to the nuclear protein CBP
Chrivia, J. C., Kwok, R. P. S., Lamb, N., Hagiwara, M., Montminy, M. R., & Goodman, R. H. (1993) · Nature · doi:10.1038/365855a0 · Cited by 2,052
The CBP co-activator is a histone acetyltransferase
Bannister, A. J., & Kouzarides, T. (1996) · Nature · doi:10.1038/384641a0 · Cited by 1,828
TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway
Schindler, C., & Darnell, J. E. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003201 · Cited by 1,808
Chen, H., Lin, R. J., Schiltz, R. L., Chakravarti, D., Nash, A., Nagy, L., Privalsky, M. L., Nakatani, Y., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80516-4 · Cited by 1,480
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- Crepieux P., 1994, Crit. Rev. Oncog., 5, 615
- Evan G. I., 1984, Mol. Cell. Biol., 4, 2843
- Nguyen, H., J. Hiscott, and P. M. Pitha. The growing family of IRF transcription factors. Cytokine Growth Factor Rev., in press.
Cited by
Sorted by citations
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 4,022
IKKε and TBK1 are essential components of the IRF3 signaling pathway
Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S.-M., & Maniatis, T. (2003) · Nature Immunology · doi:10.1038/ni921 · Cited by 2,680
Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation
Liu, S., Cai, X., Wu, J., Cong, Q., Chen, X., Li, T., Du, F., Ren, J., Wu, Y.-T., Grishin, N. V., et al. (2015) · Science · doi:10.1126/science.aaa2630 · Cited by 1,927
“S2A); phosphorylation of both IRF3 serine clusters is essential for its dimerization and activation (16, 17).”
BackgroundHonda, K., & Taniguchi, T. (2006) · Nature reviews. Immunology · doi:10.1038/nri1900 · Cited by 1,716
Triggering the Interferon Antiviral Response Through an IKK-Related Pathway
Sharma, S., tenOever, B. R., Grandvaux, N., Zhou, G., Lin, R., & Hiscott, J. B. (2003) · Science · doi:10.1126/science.1081315 · Cited by 1,685
Self-citationIRF Family of Transcription Factors as Regulators of Host Defense
Taniguchi, T., Ogasawara, K., Takaoka, A., & Tanaka, N. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.623 · Cited by 1,658
Randall, R. E., & Goodbourn, S. (2007) · Journal of General Virology · doi:10.1099/vir.0.83391-0 · Cited by 1,609
“Phosphorylation of STAT1 and its subsequent dimerization with STAT2 create a novel NLS (Banninger & Reich, 2004) and, simultaneously, phosphorylation of STAT2 inactivates the dominant constitutive nuclear export of STAT2 (Frahm et al., 2006) so that the dimers become transported into and retained in the nucleus until…”
BackgroundType I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors
Honda, K., Takaoka, A., & Taniguchi, T. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.009 · Cited by 1,386
STING Specifies IRF3 Phosphorylation by TBK1 in the Cytosolic DNA Signaling Pathway
Tanaka, Y., & Chen, Z. J. (2012) · Science Signaling · doi:10.1126/scisignal.2002521 · Cited by 1,357
“S2E), which is important for IRF3 activation (25).”
BackgroundSato, M., Suemori, H., Hata, N., Asagiri, M., Ogasawara, K., Nakao, K., Nakaya, T., Katsuki, M., Noguchi, S., Tanaka, N., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00053-4 · Cited by 1,342
Regulation and Function of IKK and IKK-Related Kinases
Häcker, H., & Karin, M. (2006) · Science s STKE · doi:10.1126/stke.3572006re13 · Cited by 1,298
The IRF Family Transcription Factors in Immunity and Oncogenesis
Tamura, T., Yanai, H., Savitsky, D., & Taniguchi, T. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090400 · Cited by 1,259
LPS-TLR4 Signaling to IRF-3/7 and NF-κB Involves the Toll Adapters TRAM and TRIF
Fitzgerald, K. A., Rowe, D. C., Barnes, B. J., Caffrey, D. R., Visintin, A., Latz, E., Monks, B. G., Pitha, P. M., & Golenbock, D. T. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031023 · Cited by 1,193
Self-citationKawai, T., Takeuchi, O., Fujita, T., Inoue, J., Mühlradt, P. F., Sato, S., Hoshino, K., & Akira, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.5887 · Cited by 1,115
“Phosphorylated IRF-3 translocates into the nucleus to induce gene expression by associating with coactivator p300/CBP (22, 37).”
BackgroundMarié, I., Durbin, J. E., & Levy, D. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.22.6660 · Cited by 1,049
“It has been reported recently that IRF3 is degraded rapidly in virusinfected cells (Lin et al., 1998; Ronco et al., 1998), resulting in the depletion of IRF3 protein at the time when IRF7 and the delayed IFNα genes are being induced.”
BackgroundInfluentialViral Subversion of the Immune System
Tortorella, D., Gewurz, B. E., Furman, M. H., Schust, D. J., & Ploegh, H. L. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.861 · Cited by 828
Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease
Foy, E. M., Li, K., Wang, C., Sumpter, R., Ikeda, M., Lemon, S. M., & Gale, M. (2003) · Science · doi:10.1126/science.1082604 · Cited by 788
The interferon response circuit: Induction and suppression by pathogenic viruses
Haller, O., Kochs, G., & Weber, F. (2005) · Virology · doi:10.1016/j.virol.2005.09.024 · Cited by 679
“IRF-3 is a member of the IFN regulatory factor (IRF) family and plays a central role in the activation of the IFN-h promoter (Lin et al., 1998; Schafer et al., 1998; Wathelet et al., 1998; Weaver et al., 1998; Yoneyama et al., 1998).”
An Atomic Model of the Interferon-β Enhanceosome
Panne, D., Maniatis, T., & Harrison, S. C. (2007) · Cell · doi:10.1016/j.cell.2007.05.019 · Cited by 625
“IRF-3 is activated by phosphorylation of C-terminal residues, leading to dimerization, nuclear translocation, and interaction with CBP/p300 ( Lin et al., 1998 ).”
Zeng, W., Sun, L., Jiang, X., Chen, X., Hou, F., Adhikari, A., Xu, M., & Chen, Z. J. (2010) · Cell · doi:10.1016/j.cell.2010.03.029 · Cited by 613
RNA recognition and signal transduction by RIG‐I‐like receptors
Yoneyama, M., & Fujita, T. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00727.x · Cited by 595
Host defense, viruses and apoptosis
Barber, G. N. (2001) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400823 · Cited by 576
Activation of Interferon Regulatory Factor 3 Is Inhibited by the Influenza A Virus NS1 Protein
Talon, J., Horvath, C. M., Polley, R., Basler, C. F., Muster, T., Palese, P., & García‐Sastre, A. (2000) · Journal of Virology · doi:10.1128/jvi.74.17.7989-7996.2000 · Cited by 578
“Several groups have demonstrated that a hallmark of IRF-3 activation in virus-infected cells is its nuclear accumulation (22, 38).”
BackgroundInterferon regulatory factors: the next generation
Mamane, Y., Heylbroeck, C., Génin, P., Algarté-Génin, M., Servant, M. J., Page, C. L., DeLuca, C., Kwon, H., Lin, R., & Hiscott, J. B. (1999) · Gene · doi:10.1016/s0378-1119(99)00262-0 · Cited by 576
Self-citationPositive feedback regulation of type I IFN genes by the IFN‐inducible transcription factor IRF‐7
Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T., & Tanaka, N. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01514-2 · Cited by 553
Grandvaux, N., Servant, M. J., tenOever, B. R., Sen, G. C., Balachandran, S., Barber, G. N., Lin, R., & Hiscott, J. B. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5532-5539.2002 · Cited by 521
“3B, lanes 5 and 6), which lacks the N-terminal DNAbinding domain (22).”
BackgroundResultInfluentialSelf-citationTaniguchi, T., & Takaoka, A. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(01)00305-3 · Cited by 476
The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3
Basler, C. F., Mikulasova, A., Martínez‐Sobrido, L., Paragas, J., Mühlberger, E., Bray, M., Klenk, H., Palese, P., & García‐Sastre, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.14.7945-7956.2003 · Cited by 476
“This carboxy-terminal serine/threonine phosphorylation of IRF-3 is thought to promote dimerization, the ability of IRF-3 to bind DNA in a sequence-specific fashion, and IRF-3 interaction with the histone acetyltransferases CBP and p300 (45, 46, 94).”
BackgroundMethodInfluentialNegishi, H., Taniguchi, T., & Yanai, H. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028423 · Cited by 467
“This holocomplex binds to target ISRE DNA sequences within the promoters of type I IFN genes (Lin et al. 1998; Sato et al. 1998; Yoneyama et al. 1998; Honda et al. 2006).”
BackgroundTriggering the Innate Antiviral Response through IRF-3 Activation
Hiscott, J. B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700002200 · Cited by 454
Self-citationCardenas, W. B., Loo, Y., Gale, M., Hartman, A. L., Kimberlin, C. R., Martínez‐Sobrido, L., Saphire, E. O., & Basler, C. F. (2006) · Journal of Virology · doi:10.1128/jvi.02199-05 · Cited by 450
“Upon viral infection, IRF-3 is phosphorylated at critical serine/threonine residues at its C terminus, triggering its homodimerization and association with cotransactivators in the nucleus (28, 37, 42, 68).”
BackgroundInfluentialInduction and Regulation of IFNs During Viral Infections
Malmgaard, L. (2004) · Journal of Interferon & Cytokine Research · doi:10.1089/1079990041689665 · Cited by 456
A conserved PLPLRT/SD motif of STING mediates the recruitment and activation of TBK1
Zhao, B., Du, F., Xu, P., Shu, C., Sankaran, B., Bell, S. L., Liu, M., Lei, Y., Gao, X., Fu, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1228-x · Cited by 447
Recognition of viruses by cytoplasmic sensors
Wilkins, C. R., & Gale, M. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.12.003 · Cited by 428
“Importantly, human herpesviruses and human immunodeficiency virus have both been shown to induce the specific degradation of IRF3 in infected cells to thus inhibit induction of antiviral genes downstream of the actions of their specific PRRs [45–48].”
Devaraj, S. G., Wang, N., Chen, Z., Chen, Z., Tseng, M., Barretto, N., Lin, R., Peters, C. J., Tseng, C.-T. K., Baker, S. C., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704870200 · Cited by 411
Self-citationClark, K., Plater, L., Peggie, M. W., & Cohen, P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000414 · Cited by 389
Barnes, B. J., Moore, P. A., & Pitha, P. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101216200 · Cited by 388
Self-citationKaiser, W. J., & Offermann, M. K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4942 · Cited by 378
Billecocq, A., Spiegel, M., Vialat, P., Kohl, A., Weber, F., Bouloy, M., & Haller, O. (2004) · Journal of Virology · doi:10.1128/jvi.78.18.9798-9806.2004 · Cited by 364
“In the case of IRF3, phosphorylation and dimerization events trigger nuclear translocation (25, 37).”
BackgroundIzaguirre, A. G., Barnes, B. J., Amrute, S. B., Yeow, W.-S., Megjugorac, N. J., Dai, J., Feng, D., Chung, E., Pitha, P. M., & Fitzgerald-Bocarsly, P. A. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603255 · Cited by 346
“In infected cells, these proteins are phosphorylated and transported to the nucleus where they interact with the transcription coactivator, transacetylases CBP/p300 [40–46].”
BackgroundSelf-citationRegulation of the type I IFN induction: a current view
Honda, K., Yanai, H., Takaoka, A., & Taniguchi, T. (2005) · International Immunology · doi:10.1093/intimm/dxh318 · Cited by 357
Lin, R., Mamane, Y., & Hiscott, J. B. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2465 · Cited by 321
“with polyclonal IRF-3 antibody (18), monoclonal Flag antibody M2 (Sigma), or”
BackgroundMethodInfluentialSelf-citationRIG-I, MDA5 and TLR3 Synergistically Play an Important Role in Restriction of Dengue Virus Infection
Nasirudeen, A. M. A., Wong, H. H., Thien, P., Xu, S., Lam, K., & Liu, D. X. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000926 · Cited by 314
“Phosphorylated IRF3 then homodimerises and translocates to the nucleus [7] to stimulate the expression of type I interferons – IFNa and IFNb.”
BackgroundBrzózka, K. D., Finke, S., & Conzelmann, K. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7673-7681.2005 · Cited by 322
“C-terminal phosphorylation of IRF-3 by TBK-1 or the inducible IKK-i is a prerequisite for IRF-3 dimerization, nuclear import, association with CBP/p300 coactivators, and activation of IFN- gene transcription.”
BackgroundAcetylation of HMG I(Y) by CBP Turns off IFNβ Expression by Disrupting the Enhanceosome
Munshi, N., Merika, M., Yie, J., Senger, K., Chen, G., & Thanos, D. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80145-8 · Cited by 325
“…of enzyme and substrates), demonstrating that the only component of the enhanceosome that can be acetylated by CBP is HMG I. Evidence supporting the involvement of IRF-3 and IRF-7 in IFNb expression has been previously published (Lin et al., 1998; Wathelet et al., 1998; Yoneyama et al., 1998).”
BackgroundThe NEMO adaptor bridges the nuclear factor-κB and interferon regulatory factor signaling pathways
Zhao, T., Yang, L., Sun, Q., Arguello, M., Ballard, D. W., Hiscott, J. B., & Lin, R. (2007) · Nature Immunology · doi:10.1038/ni1465 · Cited by 317
“VSV induced the expression of a form of IRF3 with slower migration, which corresponds to phosphorylated IRF”
BackgroundSelf-citationReview: On the Role of IRF in Host Defense
Barnes, B. J., Lubyová, B., & Pitha, P. M. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/107999002753452665 · Cited by 318
“(33) Results from several laboratories have shown that IRF-3 associates with CBP/p300, (50–52) and recently, it was shown that IRF proteins may also recruit PCAF to the IFNA promoter (B. Lubyova, unpublished observations) and ISRE.”
Self-citationHiggs, R., Gabhann, J. N., Larbi, N. B., Breen, E. P., Fitzgerald, K. A., & Jefferies, C. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1780 · Cited by 310
“inhibited IRF3 degradation in response to viral infection (8).”
BackgroundAu, W.-C., Moore, P. A., LaFleur, D. W., TOMBAL, B. F., & Pitha, P. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.44.29210 · Cited by 295
Self-citationÖsterlund, P., Pietilä, T. E., Veckman, V., Kotenko, S. V., & Julkunen, I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3434 · Cited by 301
“Expression vectors for IRF1, IRF5 (variant 2, 498 aa) (34), IRF3 (35), IRF7 (36), p50, p65 (37), RIG-I, RIG-I (18), Cardif (33), IKK , and TBK1 (17) were described elsewhere.”
Saitoh, T., Tun-Kyi, A., Ryo, A., Yamamoto, M., Finn, G., Fujita, T., Akira, S., Yamamoto, N., Lu, K. P., & Yamaoka, S. (2006) · Nature Immunology · doi:10.1038/ni1347 · Cited by 303
Moustaqil, M. D., Ollivier, E., Chiu, H.-P., van Tol, S., Rudolffi-Soto, P., Stevens, C. S., Bhumkar, A., Hunter, D. J. B., Freiberg, A. N., Jacques, D. A., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1870414 · Cited by 289
“geted for post-translational modifications upon infection [45,46], leading to its homodimerization (PDB: 1QWT, Figure 2(F)), translocation into the nucleus”
BackgroundThe role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis
Lavelle, E. C., Murphy, C. H., O'Neill, L. A. J., & Creagh, E. M. (2009) · Mucosal Immunology · doi:10.1038/mi.2009.124 · Cited by 297
Spiegel, M., Pichlmair, A., Martínez‐Sobrido, L., Cros, J. F., García‐Sastre, A., Haller, O., & Weber, F. (2005) · Journal of Virology · doi:10.1128/jvi.79.4.2079-2086.2005 · Cited by 279
“Additional treatment with calf intestinal phosphatase (40) revealed that phosphorylation was indeed responsible for the slower-migrating form of IRF-3 (data not shown).”
BackgroundInfluentialSpann, K. M., Tran, K. C., & Collins, P. L. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5353-5362.2005 · Cited by 283
“However, without continual stimulation, the phosphorylated form is exported from the nucleus and degraded by the proteosome pathway in the cytoplasm ( 21 ).”
BackgroundViral apoptosis is induced by IRF‐3‐mediated activation of Bax
Chattopadhyay, S., Marques, J. T., Yamashita, M., Peters, K. L., Smith, K., Desai, A., Williams, B. R. G., & Sen, G. C. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.50 · Cited by 281
“One such mutant of IRF-3, 396AA, is incapable of inducing gene transcription (Supplementary Figure S3A) because it lacks two critical serine residues, 396 and 398, that are targets of signalinduced phosphorylation (Lin et al, 1998).”
BackgroundLin, R., Heylbroeck, C., Génin, P., Pitha, P., & Hiscott, J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.959 · Cited by 325
“This proteinDNA complex, which was previously characterized in detail (14, 38, 39), contained CBP coactivator as confirmed by supershift analysis with the A22 antibody (Fig.”
BackgroundMethodInfluentialSelf-citationSiu, K., Kok, K., Ng, M.-H. J., Poon, V. K., Yuen, K., Zheng, B.-J., & Jin, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.008227 · Cited by 276
Yu, Y., Wang, S. E., & Hayward, G. S. (2005) · Immunity · doi:10.1016/j.immuni.2004.11.011 · Cited by 274
Positive Regulation of Interferon Regulatory Factor 3 Activation by Herc5 via ISG15 Modification
Shi, H.-X., Yang, K. S., Liu, X., Liu, X.-Y., Wei, B., Shan, Y.-F., Zhu, L.-H., & Wang, C. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01466-09 · Cited by 265
“Activation of IRF3 would result in its being modified by Ub and then degraded by the 26S proteasome, which thus terminates its transcriptional activation (3, 26).”
BackgroundLin, R., Génin, P., Mamane, Y., & Hiscott, J. B. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.17.6342-6353.2000 · Cited by 279
“IRF-3 phosphorylation ultimately results in its degradation via the ubiquitin-proteasome pathway (24, 34).”
BackgroundSelf-citationPaun, A., & Pitha, P. M. (2007) · Biochimie · doi:10.1016/j.biochi.2007.01.014 · Cited by 277
“The phosphorylated IRF-3 is under negative regulation by ubiquitin-mediated degradation [54] and it was shown that the propyl isomerase Pin1 targets activated IRF-3 for ubiquitin mediated degradation [64].”
BackgroundSelf-citationPanne, D. (2008) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2007.12.002 · Cited by 257
Lin, R., Noyce, R. S., Collins, S. E., Everett, R. D., & Mossman, K. L. (2004) · Journal of Virology · doi:10.1128/jvi.78.4.1675-1684.2004 · Cited by 268
“In the current model of virus-mediated IRF3 activation, viral infection induces the phosphorylation on multiple C-terminal serine and threonine residues of IRF3, followed by nuclear translocation and proteasome-mediated degradation (49, 82, 99).”
BackgroundInfluentialSelf-citationDNA damage-induced type I interferon promotes senescence and inhibits stem cell function
Yu, Q., Katlinskaya, Y. V., Carbone, C. J., Zhao, B., Katlinski, K. V., Zheng, H., Guha, M., Li, N., Chen, Q., Yang, T., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.069 · Cited by 260
“Intriguingly, instead of the massive IRF3 nuclear import often reported in the virus-infected cells (Lin et al., 1998), we observed limited nuclear entry and a focal pattern including some co-localization of IRF3 within the vicinity of DSB (Figures 2B and 2C).”
Sakaguchi, S., Negishi, H., Asagiri, M., Nakajima, C., Mizutani, T., Takaoka, A., Honda, K., & Taniguchi, T. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01049-0 · Cited by 264
Juang, Y.-T., Lowther, W. J., Kellum, M. J., Au, W.-C., Lin, R., Hiscott, J. B., & Pitha, P. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9837 · Cited by 266
Self-citationcGAS-mediated stabilization of IFI16 promotes innate signaling during herpes simplex virus infection
Orzalli, M. H., Broekema, N. M., Diner, B. A., Hancks, D. C., Elde, N. C., Cristea, I. M., & Knipe, D. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424637112 · Cited by 275
“Finally, HSV-1 ICP0 promotes the degradation of IFI16 in HFFs and prevents IRF-3 signaling (8).”
BackgroundInfluentialIwamura, T., Yoneyama, M., Yamaguchi, K., Suhara, W., Mori, W., Shiota, K., Okabe, Y., Namiki, H., & Fujita, T. (2001) · Genes to Cells · doi:10.1046/j.1365-2443.2001.00426.x · Cited by 265
Nair, V. P., Anang, S., Subramani, C., Abhilasha, M., Karishma, B., Srivastava, A., Shalimar, S., Nayak, B., Ranjith-Kumar, C. T., & Surjit, M. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005521 · Cited by 258
Hilton, L. S., Moganeradj, K., Zhang, G., Chen, Y., Randall, R. E., McCauley, J. W., & Goodbourn, S. (2006) · Journal of Virology · doi:10.1128/jvi.01145-06 · Cited by 251
“, NPro(1-80) encodes a protein with the first 80 amino acids of NPro and lacking amino acids 81 to 168].”
BackgroundBarro, M., & Patton, J. T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408376102 · Cited by 250
Virus Infection Leads to Localized Hyperacetylation of Histones H3 and H4 at the IFN-β Promoter
Parekh, B. S., & Maniatis, T. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80181-1 · Cited by 255
Barnes, B. J., Kellum, M. J., Field, A. E., & Pitha, P. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5721-5740.2002 · Cited by 251
“It was previously demonstrated that both IRF-3 and IRF-7 could form homo- and heterodimers in infected cells (31, 32, 38).”
BackgroundSelf-citationTriggering the Interferon Response: The Role of IRF-3 Transcription Factor
Hiscott, J. B., Pitha, P. M., Génin, P., Nguyen, H., Heylbroeck, C., Mamane, Y., Algarté-Génin, M., & Lin, R. (1999) · Journal of Interferon & Cytokine Research · doi:10.1089/107999099314360 · Cited by 244
Self-citationManipulation of the nuclear factor-κB pathway and the innate immune response by viruses
Hiscott, J. B., Nguyen, T.-L. A., Argüello, M., Nakhaei, P., & Paz, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209941 · Cited by 251
“…aa 396–405) in IRF-3 to the phosphomimetic glutamic acid generates a constitutively active form of IRF-3 (IRF-3 5D) that can efficiently transactivate IRF3-dependent promoters (Lin et al., 1998, 1999) and can stimulate cellular apoptosis in the absence of virus infection (Heylbroeck et al., 2000).”
BackgroundSelf-citationMultiple Regulatory Domains Control IRF-7 Activity in Response to Virus Infection
Lin, R., Mamane, Y., & Hiscott, J. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002814200 · Cited by 241
Self-citationHolzinger, D., Jorns, C., Stertz, S., Boisson‐Dupuis, S., Thimme, R., Weidmann, M., Casanova, J., Haller, O., & Kochs, G. (2007) · Journal of Virology · doi:10.1128/jvi.00546-06 · Cited by 241
“IRF3 is activated through the phosphorylation of serine and threonine residues in its C-terminal part (43, 82).”
BackgroundMethodThe role of Toll-like receptors in the host response to viruses
Bowie, A., & Haga, I. R. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.11.007 · Cited by 249
Prins, K. C., Cardenas, W. B., & Basler, C. F. (2009) · Journal of Virology · doi:10.1128/jvi.01875-08 · Cited by 238
“the transcription of IFN- / genes (26, 30, 55).”
BackgroundConvergence of the NF-κB and IRF pathways in the regulation of the innate antiviral response
Hiscott, J. B. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.06.002 · Cited by 239
“Transcriptional activity of IRF-3 is controlled by virus and dsRNA induced, carboxyl-terminal phosphorylation events on serines 385 and 386, as well as the serine/threonine cluster between aa396 and 405 [10–13], mediated by the IKK-related kinases—TBK-1 and IKKe [14,15].”
BackgroundSelf-citationChang, T.-H., Liao, C., & Lin, Y. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2005.06.014 · Cited by 235
Ling, Z., Tran, K. C., & Teng, M. N. (2009) · Journal of Virology · doi:10.1128/jvi.02434-08 · Cited by 230
“Expression constructs for human codon-optimized NS1 and NS2 (23) were kindly provided by Michael Holtzman (Washington University School of Medicine).”
BackgroundInfluentialDalrymple, N. A., Cimica, V., & Mackow, E. R. (2015) · mBio · doi:10.1128/mbio.00553-15 · Cited by 228
“IRF3-5D plasmids were obtained from John Hiscott (87).”
MethodGlobal and Distinct Targets of IRF-5 and IRF-7 during Innate Response to Viral Infection
Barnes, B. J., Richards, J. O., Mancl, M. E., Hanash, S., Beretta, L., & Pitha, P. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400726200 · Cited by 223
Self-citationSmith, E., Marié, I., Prakash, A., García‐Sastre, A., & Levy, D. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008717200 · Cited by 224
Bunyamwera Bunyavirus Nonstructural Protein NSs Counteracts the Induction of Alpha/Beta Interferon
Weber, F., Bridgen, A., Fazakerley, J. K., Streitenfeld, H., Kessler, N., Randall, R. E., & Elliott, R. M. (2002) · Journal of Virology · doi:10.1128/jvi.76.16.7949-7955.2002 · Cited by 221
“for monitoring ISRE activation [p(9-27)4tk ( 39)lucter] was kindly provided by”
BackgroundMethodInfluentialChang, T.-H., Kubota, T., Matsuoka, M., Jones, S. J. M., Bradfute, S. B., Bray, M., & Ozato, K. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000493 · Cited by 230
“To assess whether PIAS1 could SUMOylate an activated form of IRF7, we tested a constitutively active IRF7, called 6D, in which six serine residues in the C-terminal domain were replaced with phosphomemic aspartic acids [49].”
BackgroundServant, M. J., Grandvaux, N., tenOever, B. R., Duguay, D., Lin, R., & Hiscott, J. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209851200 · Cited by 217
Self-citationGénin, P., Algarté-Génin, M., Roof, P., Lin, R., & Hiscott, J. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5352 · Cited by 216
Self-citationLin, R., Lacoste, J., Nakhaei, P., Sun, Q., Yang, L., Paz, S., Wilkinson, P. A., Julkunen, I., Vitour, D., MEURS, E. F., et al. (2006) · Journal of Virology · doi:10.1128/jvi.02495-05 · Cited by 216
Self-citationInverse Interference: How Viruses Fight the Interferon System
Weber, F., Kochs, G., & Haller, O. (2004) · Viral Immunology · doi:10.1089/vim.2004.17.498 · Cited by 212
Burýšek, L., Yeow, W.-S., Lubyová, B., Kellum, M. J., Schafer, S. L., Huang, Y. Q., & Pitha, P. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7334-7342.1999 · Cited by 212
“Interaction between transcription factors of the IRF family, IRF-3 and IRF-7, and transcription coactivator p300 has been shown to have a functional impact (2, 21, 27, 52, 55).”
BackgroundSelf-citationMori, M., Yoneyama, M., Ito, T., Takahashi, K., Inagaki, F., & Fujita, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310616200 · Cited by 212
Zhang, Z., Zhou, H., Ouyang, X., Dong, Y., Sarapultsev, A., Luo, S., & Hu, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01252-z · Cited by 222
“As the IRF3 activation mechanism was first reported in 1998, two serine residues S396 and S386 of IRF3 were independently reported to play a more important role in IRF3 activation, which was a historical dispute.(22,71) However, a recent structural and biochemical study emphasized the importance of S383 in maintaining…”
BackgroundThe interferon antiviral response: from viral invasion to evasion
Grandvaux, N., tenOever, B. R., Servant, M. J., & Hiscott, J. B. (2002) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200206000-00008 · Cited by 216
Self-citationCrystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation
Qin, B. Y., Liu, C., Lam, S. S., Srinath, H., Delston, R. B., Correia, J. J., Derynck, R., & Lin, K. F. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb1002 · Cited by 214
Ubiquitin in the activation and attenuation of innate antiviral immunity
Heaton, S. M., Borg, N. A., & Dixit, V. M. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20151531 · Cited by 208
“IRF3 is constitutively expressed in most cell types, residing inactive in the cytosol until phosphorylation by TBK1/IKKε within two activation clusters (Ser385/Ser386 and Ser396/ Ser398/Ser402/Thr404/Ser405), resulting in homodimerization, nuclear accumulation, DNA binding, and participation in IFNB gene transcription…”
BackgroundLin, R., Génin, P., Mamane, Y., Sgarbanti, M., Battistini, A., Harrington, W. J., Barber, G. N., & Hiscott, J. B. (2001) · Oncogene · doi:10.1038/sj.onc.1204163 · Cited by 212
“…negative forms of IRF-3 and IRF-7 have been shown to interfere with IFN, RANTES and IP-10 RNA production (Au et al., 1998; Genin et al., 2000; Lin et al., 1998, 1999a; Marie et al., 1998; Sato et al., 1998; Yoneyama et al., 1998), we next determined whether vIRF-1 repressed IRF-3- or…”
BackgroundMethodInfluentialSelf-citationLin, R., Yang, L., Nakhaei, P., Sun, Q., Sharif‐Askari, E., Julkunen, I., & Hiscott, J. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m510326200 · Cited by 215
Self-citation
Metadata
- Authors
- Lin, R., Heylbroeck, C., Pitha, P. M., & Hiscott, J.
- Affiliations
- Lady Davis Institute for Medical Research (CA)
- Johns Hopkins University (US)
- Corresponding author
- Lin, Rongtuan
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1998-05-01
- Volume
- 18
- Issue
- 5
- Pages
- 2986-2996
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC110678
- OpenAlex
- W2130576390
- Semantic Scholar
- d9395b576923c5fe3c0e57a18df21bd0fd11d519
- Cited by
- 915
- References
- 69
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 24 · 2023: 26 · 2022: 33 · 2021: 24 · 2020: 30 · 2019: 26 · 2018: 27 · 2017: 28 · 2016: 33 · 2015: 26 · 2014: 38 · 2013: 42 · 2012: 30
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- IRF3, interferon regulatory factors, protein phosphorylation, Sendai virus, nuclear translocation, transcriptional activation, interferon-stimulated response element, proteasomal degradation, CREB-binding protein, transcriptional coactivator, post-translational modification, interferon-stimulated genes, phosphomimetic mutations
- MeSH terms
- Amino Acid Sequence, Animals, Biological Transport, Cell Compartmentation, Cell Nucleus, Cysteine Endopeptidases, Cytoplasm, DNA Mutational Analysis, DNA-Binding Proteins, Humans, Molecular Sequence Data, Multienzyme Complexes, Peptide Mapping, Phosphorylation, Protein Binding, Protein Processing, Post-Translational, Transcription Factors, Transcriptional Activation, Trans-Activators, Respirovirus, Proteasome Endopeptidase Complex, Interferon Regulatory Factor-3, Mice, Histone Acetyltransferases, Nuclear Receptor Coactivator 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review